A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Forasartan
Abetimus
The risk or severity of adverse effects can be increased when Abetimus is combined with Idelalisib.
Forasartan
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Idelalisib.
Forasartan
Human interferon omega-1
The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Idelalisib.
Forasartan
Briakinumab
The risk or severity of adverse effects can be increased when Briakinumab is combined with Idelalisib.
Forasartan
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Idelalisib.
Forasartan
Interferon alfa
The risk or severity of adverse effects can be increased when Interferon alfa is combined with Idelalisib.
Forasartan
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Idelalisib.
Forasartan
Brequinar
The risk or severity of adverse effects can be increased when Brequinar is combined with Idelalisib.
Forasartan
2-Methoxyethanol
The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Idelalisib.
Forasartan
Vorinostat
The risk or severity of adverse effects can be increased when Vorinostat is combined with Idelalisib.
Forasartan
Castanospermine
The risk or severity of adverse effects can be increased when Castanospermine is combined with Idelalisib.
Forasartan
Stepronin
The risk or severity of adverse effects can be increased when Stepronin is combined with Idelalisib.
Forasartan
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Idelalisib.
Forasartan
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Idelalisib.
Dihydroquinidine barbiturate
Relugolix
The serum concentration of Relugolix can be increased when it is combined with Netupitant.
Dihydroquinidine barbiturate
Berotralstat
The serum concentration of Berotralstat can be increased when it is combined with Netupitant.
Dihydroquinidine barbiturate
Pralsetinib
The serum concentration of Pralsetinib can be increased when it is combined with Netupitant.
Dihydroquinidine barbiturate
Satralizumab
The serum concentration of Netupitant can be decreased when it is combined with Satralizumab.
Dihydroquinidine barbiturate
Oliceridine
The serum concentration of Oliceridine can be increased when it is combined with Netupitant.
Dihydroquinidine barbiturate
Abametapir
The serum concentration of Netupitant can be increased when it is combined with Abametapir.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3